Related Experiment Video

Updated: Aug 20, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Strategies to overcome resistance to targeted protein kinase inhibitors

Henrik Daub1, Katja Specht, Axel Ullrich

  • 1Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 München, Germany. henrik.daub@axxima.com

Nature Reviews. Drug Discovery
|December 2, 2004
PubMed

Insights

Targeting protein tyrosine kinases treats cancer, but resistance emerges. New drugs overcome this by targeting mutated kinases, offering potent cancer therapies with reduced resistance risk.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Selective protein tyrosine kinase inhibitors are crucial cancer therapeutics.
  • Clinical resistance to kinase inhibitors, like imatinib, arises from oncogene mutations (e.g., BCR-ABL).

Purpose of the Study:

  • To leverage structural and mechanistic insights of drug-resistant kinases.
  • To identify next-generation inhibitors that overcome acquired resistance.
  • To develop novel anti-cancer strategies combining potency and resistance mitigation.

Main Methods:

  • Analysis of structural and mechanistic data from imatinib-insensitive Bcr-Abl.
  • Rational drug design for second-generation kinase inhibitors.
  • Exploration of multi-targeted inhibitors and drug cocktails.

Main Results:

  • Structural insights enable the design of drugs that bypass resistance mutations.
  • Second-generation inhibitors demonstrate potential to overcome acquired kinase resistance.
  • Development of strategies for enhanced therapeutic efficacy and reduced resistance emergence.

Conclusions:

  • Understanding resistance mechanisms is key to developing durable cancer therapies.
  • Multi-targeted inhibitors or drug combinations offer a promising approach to combatting cancer drug resistance.
  • Future cancer treatments may involve sophisticated kinase inhibitor strategies to improve patient outcomes.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...